Alnylam Pharmaceuticals
ALNY
#446
Rank
โ‚น4.713 T
Marketcap
โ‚น35,674
Share price
-2.21%
Change (1 day)
73.04%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): โ‚น15.44

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น8.05. In 2023 the company made an earnings per share (EPS) of -โ‚น315.85 an increase over its 2022 EPS that were of -โ‚น831.23.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น15.44
2023-โ‚น315.85-62%
2022-โ‚น831.2329.03%
2021-โ‚น644.23-3.36%
2020-โ‚น666.60-8.48%
2019-โ‚น728.337.67%
2018-โ‚น676.4439.74%
2017-โ‚น484.0712.94%
2016-โ‚น428.5938.84%
2015-โ‚น308.69-32.88%
2014-โ‚น459.91259.44%
2013-โ‚น127.95-31.25%
2012-โ‚น186.11

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-โ‚น111.84-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
โ‚น3,887 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น245.16-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น21.47-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น65.32-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚น658.54 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น331.57 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
โ‚น56.37 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel